Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis

Journal article

Melanie R. Shapiro, C. Wasserfall, S. Mcgrail, A. Posgai, Rhonda L. Bacher, Andrew B. Muir, M. Haller, D. Schatz, J. Wesley, M. V. von Herrath, W. Hagopian, C. Speake, M. Atkinson, T. Brusko
Diabetes, 2019

Semantic Scholar DOI PubMed

Cite

APA Click to copy
Shapiro, M. R., Wasserfall, C., Mcgrail, S., Posgai, A., Bacher, R. L., Muir, A. B., … Brusko, T. (2019). Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes.

Chicago/Turabian Click to copy
Shapiro, Melanie R., C. Wasserfall, S. Mcgrail, A. Posgai, Rhonda L. Bacher, Andrew B. Muir, M. Haller, et al. “Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis.” Diabetes (2019).

MLA Click to copy
Shapiro, Melanie R., et al. “Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis.” Diabetes, 2019.

BibTeX Click to copy

@article{melanie2019a,
  title = {Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis},
  year = {2019},
  journal = {Diabetes},
  author = {Shapiro, Melanie R. and Wasserfall, C. and Mcgrail, S. and Posgai, A. and Bacher, Rhonda L. and Muir, Andrew B. and Haller, M. and Schatz, D. and Wesley, J. and von Herrath, M. V. and Hagopian, W. and Speake, C. and Atkinson, M. and Brusko, T.}
}

Abstract

Insulin-like growth factors (IGFs), specifically IGF1 and IGF2, promote glucose metabolism, with their availability regulated by IGF-binding proteins (IGFBPs). We hypothesized that IGF1 and IGF2 levels, or their bioavailability, are reduced during type 1 diabetes development. Total serum IGF1, IGF2, and IGFBP1–7 levels were measured in an age-matched, cross-sectional cohort at varying stages of progression to type 1 diabetes. IGF1 and IGF2 levels were significantly lower in autoantibody (AAb)+ compared with AAb− relatives of subjects with type 1 diabetes. Most high-affinity IGFBPs were unchanged in individuals with pre–type 1 diabetes, suggesting that total IGF levels may reflect bioactivity. We also measured serum IGFs from a cohort of fasted subjects with type 1 diabetes. IGF1 levels significantly decreased with disease duration, in parallel with declining β-cell function. Additionally, plasma IGF levels were assessed in an AAb+ cohort monthly for a year. IGF1 and IGF2 showed longitudinal stability in single AAb+ subjects, but IGF1 levels decreased over time in subjects with multiple AAb and those who progressed to type 1 diabetes, particularly postdiagnosis. In sum, IGFs are dysregulated both before and after the clinical diagnosis of type 1 diabetes and may serve as novel biomarkers to improve disease prediction.